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Abstract
Background and Purpose: Determinants of post-acute stroke outcomes in Africa have been less investigated. We assessed
the association of metabolic syndrome (MetS) and insulin resistance with post-stroke mortality in patients with first-ever-in-
lifetime stroke in the capital city of Cameroon (sub-Saharan Africa).
Methods: Patients with an acute first-stroke event (n = 57) were recruited between May and October 2006, and followed for
5 years for mortality outcome. MetS definition was based on the Joint Interim Statement 2009, insulin sensitivity/resistance
assessed via glucose-to-insulin ratio, quantitative insulin sensitivity check index and homeostatic model assessment.
Results: Overall, 24 (42%) patients deceased during follow-up. The prevalence of MetS was higher in patients who died after
28 days, 1 year and 5 years from any cause or cardiovascular-related causes (all p#0.040). MetS was associated with an
increased overall mortality both after 1 year (39% vs. 9%) and 5 years of follow-up (55% vs. 26%, p= 0.022). Similarly, fatal
events due to cardiovascular-related conditions were more frequent in the presence of MetS both 1 year (37% vs. 9%) and 5
years after the first-ever-in-lifetime stroke (43% vs. 13%, p= 0.017). Unlike biochemical measures of insulin sensitivity and
resistance (non-significant), in age- and sex-adjusted Cox models, MetS was associated with hazard ratio (95% CI) of 2.63
(1.03–6.73) and 3.54 (1.00–12.56) respectively for all-cause and cardiovascular mortality 5 years after stroke onset.
Conclusion: The Joint Interim Statement 2009 definition of MetS may aid the identification of a subgroup of black African
stroke patients who may benefit from intensification of risk factor management.
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Introduction
Metabolic syndrome (MetS) is a constellation of conditions
which singly are associated with increased risk of cardiovascular
diseases (CVD) [1,2]. Furthermore, the presence of MetS in an
individual confers a risk of cardiovascular disease higher than that
from each of the components of the syndrome [3,4]. Therefore,
MetS has been intensively investigated over the recent years for
a possible contribution to cardiovascular disease risk stratification
and/or reduction.
The prevalence of MetS varies substantially across populations
and settings, both as a result of background differences in the
distribution of its components across populations, but also of the
diversity of criteria for defining the condition. There have been
recent efforts to harmonize the clinical definition of MetS by
accounting for ethnic differences in the cutoff values of key
components such as central obesity and atherogenic dyslipidemia
[5,6]. How the harmonized definition reflects the risk of major
outcomes has not been widely assessed. For instance, in the
absence of cutoff values specific to populations of African ethnicity,
those derived from Caucasians have been recommended in
Africans, yet no evidence is available on the correlation of MetS
based on those criteria and major incident health outcomes among
black Africans [7–10]. Stroke is the most common cardiovascular
outcome in sub-Saharan Africa and may serve this purpose.
We therefore sought to investigate the association of MetS with
post-event survival in a cohort of patients following a first-ever-in-
lifetime stroke from an urban area of Cameroon.
Methods
Study Setting and Participants
This study was conducted at Yaounde´ Central Hospital, a major
tertiary reference hospital in the capital city of Cameroon. The
setting and the study population have been previously described
[11]. Briefly, patients admitted for a first-ever-in-lifetime stroke
were consecutively enrolled between May and October 2006.
Diagnosis of stroke was based on WHO criteria [12] and stroke
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was distinguished from transient ischemic attack by the duration of
functional impairment or symptoms of more than 24 hours.
Demographic, anthropometric and clinical data were collected at
baseline using a standard questionnaire and blood samples were
collected after an overnight fast for biological determinations.
Waist circumference was measured in supine position since most
patients were bedridden for major motor deficiency and could not
assume the usual standing position required for such a measure-
ment. Body mass index was calculated using the most recent
measurement of height and weight in the last 12 months, in the
absence of specific scale for measuring adult’s weight in supine
position. Follow-up contacts were established with patients, their
relatives and/or their physicians 28 days, 1 year and 5 years from
baseline for mortality outcome data collection (Figure 1). Mortality
and causes of death were ascertained via hospital records or verbal
autopsy and based on the 10th revision of the International
Classification of Diseases (codes I 00–99) [13]. The study was
approved by the Institutional Review Board of The Yaounde´
Central Hospital (Cameroon). Patients, always in the presence of
at least one relative, or two next of kin (for unconscious patients)
provided the verbal informed consent to participate in the study.
The purpose of the study was explained to participants/family in
one of the official languages, or one of the national languages for
illiterate patients, with the assistance of translators as appropriate.
Informed verbal consent was deemed appropriate given the high
illiteracy rate among patients with stroke and the nature of the
disease with some patients presenting in unconscious or impotent
states, and therefore unable to provide a written consent. The
consent procedure was approved by the Institutional Review
Board, and documented for each patient by a tick of boxes on the
case report form, which was always presented to patients/families.
Definition of Metabolic Syndrome
MetS was defined based on the Joint Interim Statement (JIS)
criteria [5]. Thus, positive diagnosis of the syndrome was
established when at least three of the following were present: 1)
fasting plasma glucose $100 mg/dL (or history of doctor-
diagnosed diabetes), 2) systolic (and/or diastolic) blood pressure
$130 (85) mmHg or treated hypertension, 3) serum triglycerides
$150 mg/dL, 4) serum high-density lipoproteins (HDL) choles-
terol ,40 mg/dL in men and ,50 mg/dL in women and 5) waist
circumference of .80 cm in women and .94 cm in men. Blood
pressure was measured on the left arm using a mercury
sphygmomanometer with appropriate cuffs and the average of
two measurements taken 5 minutes apart was used in the study.
Analytical Methods
Glucose was analyzed by the hexokinase method (Roche
Diagnostics, Mannheim, Germany). Insulin levels were deter-
mined by radioimmunoassay (Linco Research; St. Charles, MO),
while triglycerides (TG), total cholesterol (TC) and HDL
cholesterol determinations used enzymatic colorimetric methods.
A more detailed description of the analytical methods is available
elsewhere [11]. Since none of the patients had a triglycerides level
of 400 mg/dL or more, LDL cholesterol levels were calculated
using Friedewald formula for all study participants [14]. Blood
samples were collected between 72 hours and at most 1 week post-
admission after an overnight fast of 12 hours.
Insulin sensitivity was assessed by both fasting glucose-to-insulin
(Glu/Ins) ratio and quantitative insulin sensitivity check index
(QUICKI) while insulin resistance was estimated by the Homeo-
static model assessment of insulin resistance (HOMA-IR) three to
seven days after admission [11].
Figure 1. Flow chart of enrolled patients. Values are cumulative number of participants alive (green boxes) or who died (black boxes) at 28 days,
1 and 5 years of follow-up. The number of deaths at each time-point is further distinguished as cardiovascular disease (CVD) related (light-salmon
ovals) or not (light-blue ovals).
doi:10.1371/journal.pone.0060117.g001
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Statistical Analysis
Groups’ comparison used Chi-square or Fisher’s exact tests for
categorical variables and student’s t-test or Mann-Whitney U test
for continuous variables. Results are expressed as counts
(proportions), mean and standard deviation or median, inter-
quartile range, minimum and maximum values. Early (28-day),
one- and five-year mortality rates were derived with the use of the
Kaplan-Meier estimator, with groups comparisons via Log-rank
test. Cox proportional hazard regression models were then used to
adjust for the effect of age and sex, with the non-violation of the
proportional assumption confirmed via Schoenfeld residuals’ plots.
Follow-up duration was estimated from the day of hospital
admission to death, lost to follow-up or maximum duration of 5
years, whichever came first. Because not all included patients
(n = 31/57, 54%) could afford a CT-scan, we performed
a sensitivity analysis and extrapolated our analysis to patients
clinically diagnosed with ischemic stroke (n = 45). Clinical
classification of stroke subtypes resulted in a 92% sensitivity and
60% specificity [11]. One participant was excluded from the
survival analysis for missing data on MetS status. A p value ,0.05
was used to characterize statistically significant results. SPSS v20.0
for Windows (IBM statistics, Chicago, IL, USA) and GraphPad
Prism v5.00 for Windows (San Diego, CA, USA) were used for
statistical analysis.
Results
Baseline Profile of the Study Group
The general characteristics of the study population are shown in
Table 1. Of the 57 participants included, 32 (56%) were men.
With the exception of high waist circumference which was more
frequent in women than in men (72% vs. 38%), there was no
significant difference in the distribution of baseline characteristics
between men and women (all p$0.105, Table 1). Stroke was
clinically classified as ischemic in 45 (79%) patients and as
hemorrhagic in 12 (21%) patients (Table 1). Imaging studies (CT
scan) were available for 31 patients (54%) among whom 26 (84%)
had ischemic stroke and 5 (16%) had hemorrhagic stroke [11].
Low HDL cholesterol (69%) was the most frequent component of
MetS followed by high blood pressure (65%) and high waist
circumference 53%. The prevalence of MetS was 59% (n= 33)
overall, 50% (n= 16) in men and 71% (n= 17) in women
(p = 0.196, Table 1).
Fatal Outcomes
Of the 57 patients enrolled 33 (58%) were still alive after 5 years
of follow-up. Table 2 summarizes the general characteristics of
survivors and patients who died at all follow-up time-points. Men
and women were equally distributed across all the study groups.
Stroke survivors overall were mostly comparable to those who died
with consideration to several baseline characteristics and at any
Table 1. General characteristics of the study population at inclusion.
Characteristics All patients (n=57) Men (n=32) Women (n=25) p
Age, years 61.9612.9 63.1610.4 60.4615.6 0.439
Body mass index, kg/m2 23.7611.5 25.4610.6 19.6613.0 0.160
Waist girth, cm 90.5614.0 92.1615.5 88.3611.5 0.318
Systolic blood pressure, mmHg 170636 171637 168635 0.709
Diastolic blood pressure, mmHg 101627 106633 94615 0.105
Total cholesterol, mg/dL 173636 169640 178639 0.389
Triglycerides, mg/dL 129656 135657 122655 0.411
LDL cholesterol, mg/dL 109643 106640 114647 0.483
HDL cholesterol, mg/dL 37621 36614 39628 0.528
Fasting blood glucose, g/L 1.3360.79 1.2060.51 1.4761.03 0.205
Plasma insulin, mIU/L 5.8665.37 5.263.3 6.767.4 0.316
Clinical type of stroke
Hemorrhagic, n (%) 12 (21) 7 (22) 6 (24) .0.99
Ischemic, n (%) 45 (79) 25 (78) 20 (80) .0.99
Components of MetS
High blood pressure, n (%) 37 (65) 22 (69) 15 (60) 0.684
Diabetes, n (%) 26 (47) 15 (50) 11 (44) 0.657
High waist girth, n (%) 30 (53) 12 (38) 18 (72) 0.010
Low HDL cholesterol, n (%) 38 (69) 19 (59) 19 (83) 0.123
High triglyceride, n (%) 22 (40) 14 (44) 8 (35) 0.696
Metabolic syndrome, n (%) 33 (59) 16 (50) 17 (71) 0.196
Number of components, n (%)
1 8 (14) 5 (16) 3 (13) .0.99
2 15 (27) 11 (34) 4 (17) 0.223
3 20 (36) 10 (31) 10 (42) 0.601
4 or 5 13 (24) 6 (19) 7 (30) 0.494
doi:10.1371/journal.pone.0060117.t001
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given time-point during follow-up. Although they tended to be
younger, leaner, to have lower fasting blood glucose, insulin,
triglycerides, HDL cholesterol and LDL cholesterol levels, and to
display lower systolic and diastolic blood pressures than those who
died, differences did not reach the conventional significance
threshold (Table 2). Similar findings were observed in the subset of
patients clinically diagnosed with ischemic stroke (Table S1).
Metabolic Syndrome and Insulin Resistance
The distribution of individual components of MetS was similar
between survivors and deceased participants at any time-point.
However, the prevalence of JIS-defined MetS was always higher
among deceased patients. Prevalence figures (deceased vs.
survivors) were 11/12 vs. 22/45 at 28 days, 13/15 vs. 20/42 at
1 year, 18/24 vs. 15/33 at 5 years for all-cause mortality, and 14/
17 vs. 19/40 at 5 years for cardiovascular-related death (all
p#0.04, Table 2). No difference in the prevalence of individual
components of MetS was observed although deceased patients
from cardiovascular-related causes at 5-year among those with
clinically diagnosed ischemic stroke had a higher waist circumfer-
ence (Table S1).
As previously mentioned, HOMA-IR was used to evaluate
insulin resistance while QUICKI and the Glu/Ins ratio were used
as surrogates of sensitivity to insulin. Figure 2 shows that there was
no significant difference between stroke survivors and those who
died with regard to the levels of those predictors of insulin
response. Although deceased patients tended to be more insulin-
resistant (and less insulin-sensitive) than their counterparts, overall,
no significant difference was observed in insulin sensitivity
(glucose-to-insulin ratio and QUICKI) and resistance indices
(HOMA-IR) between the two groups.
Kaplan Meier and Cox Regression Analysis
Mortality rate from all causes and from cardiovascular-related
causes in patients with first-ever-in-lifetime stroke was respectively
43% (95% CI, 30–56%) and 31% (95% CI, 18–43%) after 5 years.
This and the stratification according to presence of MetS are
illustrated in Figure 3. Overall mortality occurred more often in
patients with MetS (Log-rank test, p=0.022; Figure 3A). The latter
group had a higher mortality rate both after 1 and 5 years follow-
up (39% vs. 9% and 55% vs. 26% respectively). Survival analysis
in patients who died from cardiovascular-related conditions
suggests that 14/17 (82%) of deaths occurred within 12 months
and the majority of deceased patients 14/17 (82%) had MetS.
Mortality rates associated to MetS at 1 and 5 years were
respectively 37% (20–53%) and 43% (26–60%). The 5-year
mortality rate was significantly higher in the presence of MetS
than in its absence (p=0.017, Figure 3B). When patients with
ischemic stroke were considered, 12/17 (71%) of deceased patients
within 5 years had MetS which was associated with a 50%
Table 2. Baseline characteristics of the study population according to mortality at different follow-up time-points.
Characteristics
Short term overall
mortality 1-year overall mortality 5-year overall mortality
5-year cardiovascular-related
mortality
Yes
(n =12)
No
(n=45) p
Yes
(n =15)
No
(n=42) p
Yes
(n =24)
No
(n =33) p
Yes
(n =17)
No
(n =40) p
Age, years 68612 60612 0.086 66613 60613 0.135 65612 59613 0.092 64.3613.1 60.9612.8 0.368
Sex ratio, men/women 5/7 27/18 0.255 7/8 25/17 0.389 13/11 19/14 0.798 8/9 24/16 0.542
Body mass index, kg/m2 25613 23611 0.718 27612 23611 0.353 26613 23611 0.477 26.9611.0 22.7611.7 0.348
Waist girth, cm 92610 90615 0.655 94613 89614 0.265 93613 89615 0.267 94.9611.9 88.5614.5 0.114
Systolic blood pressure, mmHg 159637 173636 0.246 159636 174636 0.185 163635 174636 0.242 164635 172637 0.488
Diastolic blood pressure, mmHg 90615 104629 0.130 91616 104630 0.127 94615 106633 0.094 94615 104631 0.212
Total cholesterol, mg/dL 185636 169640 0.229 173641 172639 0.941 170639 175641 0.664 171637 173641 0.893
Triglycerides, mg/dL 132650 129658 0.842 136654 127657 0.599 126656 132656 0.675 122648 132660 0.527
LDL cholesterol, mg/dL 125641 105643 0.171 113645 108643 0.714 112643 107644 0.714 112641 108644 0.765
HDL cholesterol, mg/dL 34617 38621 0.516 33617 39622 0.362 33615 41624 0.168 35617 38622 0.591
Fasting blood glucose, g/L 1.6260.99 1.2560.72 0.159 1.4960.91 1.2660.75 0.355 1.3660.79 1.3160.81 0.815 1.4660.88 1.2760.76 0.422
Plasma insulin, mIU/L 5.062.6 6.165.9 0.533 4.862.7 6.366.0 0.374 5.665.5 6.065.3 0.775 6.666.1 5.565.0 0.506
Components of MetS
High blood pressure, n (%) 9 (75) 28 (62) 0.510 11 (73) 26 (62) 0.537 18 (75) 19 (56) 0.174 13 (77) 24 (60) 0.374
Diabetes, n (%) 8 (67) 18 (42) 0.128 9 (60) 17 (43) 0.247 13 (54) 13 (42) 0.368 10 (59) 16 (42) 0.392
High waist girth, n (%) 8 (67) 22 (49) 0.340 10 (67) 20 (48) 0.205 15 (62) 15 (45) 0.203 12 (71) 18 (45) 0.139
Low HDL cholesterol, n (%) 9 (75) 29 (67) 0.735 11 (73) 27 (67) 0.754 18 (75) 20 (64) 0.404 12 (32) 26 (68) .0.99
High triglyceride, n (%) 5 (42) 17 (39) 0.894 6 (40) 16 (40) 1.00 8 (33) 14 (45) 0.375 5 (29) 17 (45) 0.439
Metabolic syndrome, n (%) 11 (92) 22 (50) 0.010 13 (87) 20 (49) 0.014 18 (75) 15 (47) 0.034 14 (82) 19 (49) 0.040
Number of components, n (%)
1 1 (8) 7 (16) 0.672 1 (7) 7 (17) 0.428 3 (12) 5 (16) 1.00 2 (12) 6 (15) .0.99
2 0 (0) 15 (34) 0.024 1 (7) 14 (34) 0.047 3 (12) 12 (37) 0.065 1 (6) 14 (36) 0.023
3 6 (50) 14 (31) 0.313 8 (53) 12 (29) 0.096 10 (42) 10 (31) 0.421 8 (47) 12 (31) 0.386
4 or 5 5 (42) 8 (19) 0.096 5 (33) 8 (20) 0.300 8 (33) 5 (16) 0.136 6 (35) 7 (18) 0.190
doi:10.1371/journal.pone.0060117.t002
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(95%CI, 30–70%; data not shown) all-cause mortality rate as
opposed to 25% (95%CI, 6–44%; data not shown) among their
counterparts without MetS (p=0.047). In this subset of the study
population, cardiovascular-related mortality occurred significantly
earlier in the presence of MetS, 42 (95%CI, 22–62%; data not
shown) vs. 10% (95%CI, 0–23%; data not shown), p=0.017
(Figure S1).
In age- and sex-adjusted Cox regression analysis, the presence
of MetS was associated with a hazard ratio (95% CI) of 2.63 (1.03–
6.73), p=0.043 and 3.54 (1.00–12.56), p=0.050 respectively for
all-cause and cardiovascular-related mortality after five years.
Markers of insulin sensitivity or insulin resistance were not
associated with 5-year mortality (all p.0.05, Table 3). Similarly,
none of the components of MetS taken separately was significantly
associated with mortality risk (data not shown). In patients with
ischemic stroke, none of the candidate markers reached statistical
significance for the prediction of overall mortality (all p.0.05)
while MetS tended to be associated with 5-year mortality from
cardiovascular-related conditions (p=0.048, Table S2).
Discussion
We have investigated the relationship between post-stroke
mortality and MetS using the recent definition criteria by the Joint
Interim Statement for harmonization of MetS [5]. In our cohort,
the prevalence of MetS but not its components was higher in
stroke patients who died after 28 days, 1 and 5 years even after
adjustment for age and gender. This was observed for both all-
cause and cardiovascular-related mortality but with a less robust
association with the latter.
Previous studies of MetS in sub-Saharan Africa used a variety of
definitions including the ones proposed by the International
Diabetes Federation, the World Health Organization (WHO) and
the National Cholesterol Education Panel (NCEP) Adult Treat-
ment Panel III [15]. The prevalence of MetS varies according to
the criteria used for its definition in various ethnic groups and the
JIS definition may result in a better estimate of the syndrome in
sub-Saharan populations [5,16,17]. We found that hypertension
and low HDL cholesterol were the most prevalent components of
Figure 2. Insulin sensitivity and resistance according to outcome and cause of death during follow-up. Comparison of insulin resistance
and sensitivity indices according to the vital status at 28 days (A), 1 year (B), 5 years from all-cause of death (C) and 5 years cardiovascular-related
mortality (D). Data are expressed in a log scale. Boxes represent median (crossing horizontal bar) and interquartile range (lower and upper limits). The
whiskers depict maximum and minimum values for each of the insulin resistance/sensitivity indices for deceased patients (red color) and those still
alive (blue color) at the indicated follow-up time. For each insulin resistance/sensitivity index, and across figure panels, the boxes and whiskers for the
deceased are always displayed on the right.
doi:10.1371/journal.pone.0060117.g002
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MetS in both survivors and deceased patients without significant
differences between the two groups for all components. Moreover,
MetS was more prevalent among fatal stroke cases. This suggests
that risk of stroke onset at baseline from the individual risk factors
in all patients is the same but they tend to occur concomitantly and
therefore increase mortality rate in deceased patients. Similar
findings have been described in African-Caribbean population
with stroke and coronary heart disease [18].
Unlike insulin resistance or sensitivity indices, in the presence of
MetS, patients with ischemic stroke died significantly faster
independently of the cause of death. Overall, MetS was associated
with a higher mortality rate and was an independent predictor of
5-year post-stroke death independently of the cause. A similar
trend was observed for deaths from cardiovascular-related
conditions. This finding is consistent with previously reported
data using other definitions of MetS. In a logistic regression
analysis and using WHO criteria for diagnosis of MetS, Isomaa
et al. reported a 1.81 relative risk of death from cardiovascular-
related events over a follow-up duration of 6.9 years [19]. Other
significant predictors in the study include hypertension and
microalbuminuria. The latter has not been assessed in our study
and the former is estimated by the WHO criteria using a higher
Figure 3. Kaplan-Meier curves in all included patients. Overall (A) and cardiovascular-related (B) mortalities according to the presence of
metabolic syndrome. Comparisons were performed using Log-rank test. The total fraction of deceased patients during follow-up is indicated above
each arm in the 2 panels. Cumulative number of deceased patients during follow-up and mortality rates (95%CI) after 1 and 5 years from overall and
cardiovascular-related causes for all patients and in the presence or absence of MetS are indicated below the respective graphs.
doi:10.1371/journal.pone.0060117.g003
Table 3. Cox regression analysis of 5-year mortality in all study participants.
5-year overall mortality 5-year cardiovascular-related mortality
Covariates HR* 95%CI p HR 95%CI p
Glu/Ins ratio{ 0.81 0.42–1.55 0.527 0.68 0.24–1.97 0.480
HOMA-IR{ 1.04 0.88–1.22 0.673 1.08 0.92–1.26 0.371
QUICKI1 0.06 0–16.88 0.331 0.10 0–10.36 0.171
Metabolic syndrome 2.63 1.03–6.73 0.043 3.54 1.00–12.56 0.050
All Cox models are adjusted for age and gender;
*hazard ratio;
{glucose-to-insulin ratio;
{homeostatic model assessment of insulin resistance;
1quantitative insulin sensitivity check index.
doi:10.1371/journal.pone.0060117.t003
Metabolic Syndrome and Post-Stroke Mortality
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cutoff for blood pressure. Similarly, other studies defining MetS
according to the NCEP or WHO have shown an increased
mortality associated with the condition [4,20,21]. More impor-
tantly, it is apparent from our results that cardiovascular mortality
occurs more often few months after stroke onset in patients with
MetS. This suggests that targeting MetS might be effective for
prevention of early mortality associated to cerebrovascular events.
However, it is worthwhile to notice that our observations are based
on a model restricted to metabolic parameters. The interplay
between MetS and other variables such as stroke severity or the
stroke subtype might influence the resulting outcome.
Unlike the pathophysiology of cardiovascular events in individ-
uals with MetS, the relationship between MetS and mortality
following cardiovascular events in general and stroke in particular
still needs to be clarified [22]. The differences in definition and
heterogeneity in populations of interest in studies focusing on
MetS make the findings difficult to pool together. For instance, in
some reports, participants were enrolled based on diabetes status,
gender or age and in others not [2,3,23–25]. Nevertheless, in
recent meta-analysis, both Galassi et al. and Gami et al. have
shown that independently of these differences, MetS is associated
with an increased risk of death following a cardiovascular event
[20,26]. Whether or not this excess mortality risk is due to the
constellation of factors included in the definition of MetS is still
unclear. Consistent with what has been described in other settings,
our findings suggest that MetS is more prevalent and might predict
poor outcome in patients with first-ever-in-lifetime stroke.
However, no further inference about the relationship between
the number of risk factors and mortality can be made due to the
relatively small sample size.
The small sample size is the major limitation of this study. This
may have affected our capacity for detecting some significant
differences and precluded stratification according to stroke
subtypes. Moreover, in the absence of systematic CT-Scan or
magnetic resonance imaging studies, the definitive diagnosis of the
subtypes of stroke was not available for all participants. Some
patients with acute stroke would tend to die prior to hospital
admission in this setting; therefore our use of hospital-based cohort
would underestimate the true magnitude of early post-stroke
mortality. We also lack data on medication prescription and
adherence during follow-up, which could aid the understanding of
some of the associations observed in this study. Lastly, waist girth
was measured in supine position, and BMI calculated based on
imputed weight using the most recent measurement in the last 12
months. Both approaches are imprecise, but are among the best
alternatives for approximating those parameters in bedridden
patients in our resources-limited setting. Our study also has major
advantages including extensive baseline investigation, and a suc-
cessful follow-up of a relatively large number of participants, which
is rather uncommon in the African setting [8]. By demonstrating
a correlation between JIS-defined MetS and long-term outcome,
we have provided evidence in support of the applicability of this
definition, although larger studies will be needed to assess the
validity of individual components of the syndrome based on JIS
definition in this context.
In conclusion, JIS-defined MetS is associated with an increased
cardiovascular-related and all-cause mortality in black African
patients with first stroke event. MetS therefore appears as a useful
tool for identifying a subgroup of patients with stroke whose long-
term outcomes can potentially be improved by more intensive risk
factor modifying therapies. However, our observations need to be
confirmed in a bigger cohort and the process by which the
combination of risk factors in MetS influences case fatality
warrants further investigation. In such a cohort, further in-
vestigation of the relationship between MetS as defined by the JIS
2009 [5] criteria and stroke severity using currently available
scores could also be addressed.
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